Ebastine overdose in a child by Pecoraro, Luca et al.
CASE REPORT
Ebastine overdose in a child
Luca Pecoraro , Giulia Paiola & Angelo Pietrobelli
Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, Italy
Correspondence
Luca Pecoraro, Department of Surgical
Sciences, Dentistry, Gynecology and
Pediatrics, University of Verona, Piazzale
Ludovico Antonio Scuro 10, Verona 37134,
Italy. Tel: +39 0458027454; Fax: +39 045/
8124790; E-mail: lucapecoraro88@libero.it
Funding Information
No sources of funding were declared for this
study.
Received: 18 August 2016; Revised: 1
January 2017; Accepted: 9 January 2017
Clinical Case Reports 2017; 5(4): 403–405
doi: 10.1002/ccr3.845
Key Clinical Message
The lack of side effects after acute ingestion of a high dose of ebastine in our
child aging 44 months suggests an overall safety profile of ebastine; it could
suggest less time of hospitalization for children who are subjected to this event.
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To the Editor
A three-year-and-eight-month-old child, 14.5 kg, was
brought to our emergency room (ER) 40 min after invol-
untary ingestion of six 10 mg ebastine film-coated tablets
(total intake: 60 mg). The child’s clinical history revealed
no chronic diseases, past acute infectious events, and no
intake of other drugs. The mother related the onset of
her child’s drowsiness after the ingestion of the tablets.
Impairment of consciousness lasted 20 min followed by
sudden recovery. The child did not complain for head-
ache, dizziness, dryness of the mouth, palpitations, or any
abdominal symptoms. The mother reported the absence
of any treatment attempts before arriving at our ER. The
child appeared in good general conditions at physical
examination, with neither behavioral changes nor altered
state of consciousness, no cardiorespiratory, or abdominal
abnormalities. Vital signs were normal: heart rate 91 beats
per minute with normal electrocardiogram (ECG) and
QTc values, sinus rhythm, 100% oxygen saturation
(SaO2) in room air and spontaneous breathing, body
temperature 36.6°C. Red cells, white cells, platelets, crea-
tinine, albumin, and alanine transaminase were normal.
The patient presented normal values for venous blood
gases. In agreement with the advice of the poisoning cen-
ter, the child was hospitalized with oxymetry monitoring
for 48 h. Five grams of activated charcoal was adminis-
tered. ECG, complete blood count (CBC), and blood
chemistry tests, repeated after 24 h, remained normal.
During hospitalization, the child did not suffer from neu-
rological, cardiorespiratory, or gastroenterological symp-
toms; diuresis was normal. No fever during the
hospitalization. The child was discharged in good general
conditions 48 h after her arrival in our ER.
Ebastine is a second-generation antihistamine, used for
symptomatic treatment of allergic rhinitis and urticaria [1].
It binds to the H1 histamine receptor, preventing its
activation determined by an allergic reaction.
Ebastine 10 mg tablet (the type of the formulation
taken by the child) is not allowed to children under
12 years; in fact, the safety and efficacy in these patients
has not been studied [1].
Due to this evidence, the use of ebastine tablets is
allowed only for subjects over 12 years of age.
Most guidelines report that appropriate dosage is
10 mg tablet once a day. An intake of 20 mg/day is
reported to be tolerated [1].
In children, the formulation allowed in some countries is
the syrup; in particular, guidelines have authorized its use in
children aged 6–12 years at the dosage of 5 mg/day.
Furthermore, different guidelines have allowed the use in
children aged 2–5 years at the dosage of 2.5 mg/day [2].
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Potency of ebastine, at the dosage of 10 mg, is less
powerful than cetirizine and terfenadine [3]; instead,
ebastine has more potency than fexofenadine and lorata-
dine. Ebastine 20 mg tablet has higher efficacy in compar-
ison with cetirizine (10 mg) or loratadine (10 mg) [4].
Antihistamines overdose represents an important
problem in pediatric age. In the literature, we found
multiple cases of children who experienced a first-gen-
eration antihistamines overdose, particularly diphenhy-
dramine [5]. Some adverse effects resulting from the use
of these drugs are due to the fact that they provoke a
poorly selective action on H1 receptors, because they
can also interact with no histamine receptors (mainly
serotonergic, cholinergic, and alpha-adrenergic). Specifi-
cally, the most serious effects of overdose are due to
abnormalities in signal conduction and heart rhythm
(consequent to the block of potassium channels that
control the phase of cardiac repolarization [6]) and to
neurological involvement (due to the accumulation of
the molecule, dispensed to high doses and highly lipo-
philic, within the CNS) with convulsions which may be
followed (at high doses) by states of coma, occasionally
irreversible [7].
The second-generation antihistamines have many
advantages over first-generation antihistamines, in partic-
ular a low lipid solubility, which determines a reduced
capacity, to normal dosages, to cross the blood-brain bar-
rier. Consequently, second-generation antihistamines bind
exclusively to the H1 receptor, characteristic which deter-
mines the lack of occurrence of all adverse reactions due
to the binding to the nonhistamine receptors.
The risk of nonsedative antihistamines overdose,
including ebastine, is represented by tachycardia, abnor-
mal behavior, headache, dizziness, oliguria, and gastroin-
testinal disorders [1, 8]. These symptoms are explained by
the fact that second-generation antihistamines are metab-
olized in the liver by the cytochrome P450. So they arise
in two types of events: first of all, their overdose: It takes
to a saturation and consequently to an inhibition of this
system and secondly, their concomitant consumption
(particularly terfenadine or astemizole) with drugs which
are able to inhibit cytochrome P450. These two side
effects can cause an abnormal accumulation of these
agents and their metabolites in the body with the risk of
possible side reactions, especially at cardiac level (i.e.,
tachyarrhythmia, torsades de pointes, QT prolongation)
[6].
Concerning ebastine overdose, there are few clinical
studies in the literature involving only adults, and to the
best of our knowledge, we did not find any study includ-
ing children. Moss et al. showed no clinically relevant
effect of the drug on QTc interval at the recommended
doses of 10 and 20 mg/day in adults. Besides, when it is
administered at ordinary doses, with ketoconazole or ery-
thromycin (also metabolized by the cytochrome P450),
the overall effect on the QTc interval does not appear to
be clinically significant [9]. The same was reported when
ebastine tablets were administered in the amount of
60 mg/day (three times the recommended dose) for a
week or 100 mg of ebastine in a single dose [10].
Starting from this case report and the limited informa-
tion on second-generation antihistamine overdose, it
could be possible to consider new strategies for its treat-
ment. The actual treatment of this condition consists of
administrating activated charcoal to patients presenting
within an hour of ingesting substantial amounts of this
type of antihistamines. Cardiovascular monitoring is also
important. Because of their capacity to cause tachycardia
and the uncertainty about the potential of antihistamines
to cause arrhythmias in overdose, an ECG should be per-
formed and the QRS and QT intervals assessed. Patients
with abnormal ECGs or signs of evolving toxicity should
undergo ECG monitoring. Furthermore, it has been sug-
gested that adults that did not develop any adverse reac-
tions from ebastine overdose in the first six hours after
ingestion have no risk of later symptoms [8]; our findings
suggest that this might be the case also in young children.
The lack of side effects after acute ingestion of a high
dose of ebastine in our three-year-and-eight-month-old
child suggests an overall safety profile of ebastine at the
maximum dosage of 60 mg.
Actually, there are few scientific studies regarding sec-
ond-generation antihistamines overdose, very few studies
regarding it in children, and no study regarding ebastine
overdose in children.
In conclusion, this case report could be helpful because
a strategy of toxicological management of antihistamine
overdose has been proposed and it could lead to new ques-
tions about the use of ebastine in children: Also, it could
increase the variety of second-generation antihistamines
available to the pediatrician in allergic rhinitis and urticaria
and reduce the time of observation when children, without
clinical signs, take an overdose of ebastine.
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